Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis

被引:54
作者
Guengerich, FP
Hanna, IH
Martin, MV
Gillam, EMJ
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA
[3] Schering Plough Corp, Res Inst, Dept Drug Metab & Safety Assessment, Kenilworth, NJ 07033 USA
[4] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
关键词
D O I
10.1021/bi027085w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human cytochrome P450 (P450) 2D6 is an important enzyme involved in the metabolism of drugs, many of which are amines or contain other basic nitrogen atoms. Asp301 has generally been considered to be involved in electrostatic docking with the basic substrates, on the basis of previous modeling studies and site-directed mutagenesis. Substitution of Glu216 with a residue other than Asp strongly attenuated the binding of quinidine, bufuralol, and several other P450 2D6 ligands. Catalytic activity with the substrates bufuralol and 4-methoxyphenethylamine was strongly inhibited by neutral or basic mutations at Glu216 (>95%), to the same extent as the substitution of Asn at Asp301. Unlike the Asp301 mutants, the Gln216 mutant (E216Q) retained 40% enzyme efficiency with the substrate spirosulfonamide, devoid of basic nitrogen, suggesting that the substitutions at Glu216 affect binding of amine substrates more than other catalytic steps. Attempts to induce catalytic specificity toward new substrates by substitutions at Asp301 and Glu216 were unsuccessful. Collectively, the results provide evidence for electrostatic interaction of amine substrates with Glu216, and we propose that both of these acidic residues plus at least another residue(s) is (are) involved in binding the repertoire of P450 2D6 ligands.
引用
收藏
页码:1245 / 1253
页数:9
相关论文
共 78 条
[1]   ANIMAL MODELING OF HUMAN POLYMORPHIC DRUG OXIDATION - THE METABOLISM OF DEBRISOQUINE AND PHENACETIN IN RAT INBRED STRAINS [J].
ALDABBAGH, SG ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (03) :161-164
[2]   Crystal structure of the F87W/Y96F/V247L mutant of cytochrome P-450cam with 1,3,5-trichlorobenzene bound and further protein engineering for the oxidation of pentachlorobenzene and hexachlorobenzene [J].
Chen, XH ;
Christopher, A ;
Jones, JP ;
Bell, SG ;
Guo, Q ;
Xu, F ;
Rao, ZH ;
Wong, LL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (40) :37519-37526
[3]   Metabolism of amitriptyline with CYP2D6 expressed in a human cell line [J].
Coutts, RT ;
Bach, MV ;
Baker, GB .
XENOBIOTICA, 1997, 27 (01) :33-47
[4]   INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS [J].
COUTTS, RT ;
SU, P ;
BAKER, GB .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) :177-186
[5]  
COUTTS RT, 1994, DRUG METAB DISPOS, V22, P756
[6]   COMPARISON OF SUBSTRATE METABOLISM BY WILD-TYPE CYP2D6 PROTEIN AND A VARIANT CONTAINING METHIONINE, NOT VALINE, AT POSITION-374 [J].
CRESPI, CL ;
STEIMEL, DT ;
PENMAN, BW ;
KORZEKWA, KR ;
FERNANDEZSALGUERO, P ;
BUTERS, JTM ;
GELBOIN, HV ;
GONZALEZ, FJ ;
IDLE, JR ;
DALY, AK .
PHARMACOGENETICS, 1995, 5 (04) :234-243
[7]   Substrate-assisted catalysis in cytochrome P450eryF [J].
CuppVickery, JR ;
Han, O ;
Hutchinson, CR ;
Poulos, TL .
NATURE STRUCTURAL BIOLOGY, 1996, 3 (07) :632-637
[8]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[9]  
DAYER P, 1986, BIOCHEM PHARMACOL, V34, P399
[10]   A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) :4062-4070